Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Active, not recruiting · Phase 3 · NCT04379635
Conditions: Non Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $4,380
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 453
About the trial
- Sponsor
- BeiGene
- Tested
- Tislelizumab (drug), Cisplatin injection (drug), Paclitaxel injection (drug), Pemetrexed Disodium (drug), Placebos (drug), Carboplatin (drug)
- Dates
- Started 2020-05-29; completion 2027-03-31
- Results posted
- Not yet
The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed by placebo as adjuvant treatment.
From ClinicalTrials.gov, last updated 2026-03-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines (shanghai) Co. Ltd reported $4,380 in research payments for this study in 2025 (4 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sbq Radiology, PLLC $4,380
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.